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ABSTRACT: 
 
OBJECTIVE:  To determine how the synthetic skin substitute Biobrane® compares to silver 
sulfadiazine (SSD, Silvadene®) in the treatment of patients with low body surface area partial 
thickness burns. 
STUDY DESIGN:  Systematic literature review of all English language articles of primary 
studies published between February 1990 and November 2004. 
DATA SOURCES:  Randomized controlled trials comparing Biobrane with silver sulfadiazine 
were identified from MEDLINE, The Cochrane Central Registrar of Controlled Trials, and 
BioMed Central. 
OUTCOMES:  Measured outcomes included: healing time, length of hospital stay, amount of 
pain, and development of treatment complications. 
RESULTS:  Three trials comparing Biobrane to silver sulfadiazine found a significantly 
decreased amount of healing time in those subjects treated with Biobrane.  Two of the three trials 
studied and found a significantly decreased length of hospital stay and a significantly decreased 
amount of pain in the Biobrane-treated subjects.  Each of the three trials reported complications, 
which were not significant when comparing Biobrane to SSD.  After combining the studies, 
calculations showed an overall decrease in the healing time, pain scores, and length of hospital 
stay. 
CONCLUSIONS:  Evidence provided by these three trials suggests Biobrane is more effective 
than silver sulfadiazine at reducing healing time, length of hospital stay, and amount of pain in 
the treatment of partial-thickness thermal burn injuries.  Although Biobrane does not have the 
anti-bacterial effects of silver sulfadiazine, the decreased number of dressing changes with 
Biobrane likely decreases pain and lessens the opportunity for wound exposure to infectious 
organisms or contaminants.  Two of the three studies focused primarily on pediatric patients, 
however the results were similar throughout all age ranges. 
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INTRODUCTION: 
There are roughly 1 million burn injuries that occur each year, 700,000 of these result in visits to 
the emergency department.
1
  In the United States, as well as much of the world, treatment of 
partial-thickness burns is accomplished through the use of topical antimicrobials—one of the 
most common and popular of these being silver sulfadiazine (SSD, Silvadene®).  SSD treatment 
usually consists of daily or twice daily dressing removal, wound debridement, and reapplication 
of SSD.
2,3
  This process is commonly painful and time consuming for the patient or caregiver.  A 
potential alternative to topical antimicrobials is the use of synthetic materials such as Biobrane® 
to cover the wound site.
4
  Biobrane is a semipermeable membrane with porcine (swine) dermal 
collagen bonded to a nylon and silicon mesh.
5 
  
A systematic review was conducted to determine how Biobrane compares to SSD with use in the 
treatment of low body surface area (BSA) partial-thickness (2
nd
 degree) thermal burns. 
METHODS: 
Literature searches were performed using the following databases:  MEDLINE (1990-2004), The 
Cochrane Central Register of Controlled Trials (through 4
th
 quarter 2004), and BioMed Central 
(1997-2004).  Searches were restricted to the English language and human subjects, using the 
key-words:  “burns,” “silver sulfadiazine,” “Biobrane,” “biocompatible materials,” “occlusive 
dressings,” and “biological dressings.”  All randomized controlled trials (RCT) that compared 
Biobrane with SSD were attempted to be located. 
Trials that were included met the following inclusion criteria:  (1)-Compared Biobrane with 
SSD, (2)-Randomization was used, (3)-Studied subjects with partial-thickness thermal burns less 
than 20% total BSA, (4)-Studied, at minimum, healing time of burn wounds and complications.  
Exclusion criteria consisted of:  (1)-No randomization evident, (2)-Comparing products other 
than Biobrane with SSD, (3)-Studied subjects with superficial or full thickness burns, (4)-Studied 
subjects with burns greater than 20% BSA, (5)-Studied subjects with burn injuries over 48 hours 
old or wounds that were grossly contaminated or obviously infected. 
Each trial was reviewed for the inclusion and exclusion criteria and trial data was reviewed for 
statistical significance—which was considered a p-value less than 0.05.   
RESULTS: 
Included Studies 
Literature searches and subsequent review revealed three randomized controlled trials.  The 
characteristics of each included RCT study are shown in Table 1.  Each of the three trials 
specifically studied Biobrane and SSD in the treatment of partial-thickness burns.  All three of 
the studies reported wound healing times and complications of treatment.  In addition, two of the 
three trials studied duration of hospital stays, pain levels and the use of analgesics.  Two of the 
three trials focused primarily on pediatric and adolescent subjects, the third included subjects of 
all ages.   
The inclusion criteria for the individual studies allowed percent BSA burned to be as high as 
29%; however, the mean burned BSA for each study ranged approximately between 2% and 
12%.  The limit of 20% burned BSA was observed for this review. 
A fourth trial was excluded because it studied TransCyte®—a product that uses a biological 
material derived from newborn human foreskins cultured on the Biobrane mesh—compared to 
SSD.  Although this trial did show similar results as the included three, it did not specifically 
study Biobrane; therefore, it was not possible to determine to what extent the results were 
affected by the biological material coating the Biobrane mesh. 
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Table 1 
 
Characteristics of studies included in the systematic review of Biobrane versus Silver 
Sulfadiazine in the treatment of partial-thickness burns 
 
Study Barret 2000 Gerding 1990 Lal 1999 
Type of Study Prospective, 
Randomized Controlled 
Trial (RCT) 
Prospective RCT Prospective RCT 
N-value 20 64 89 
Age (mean yrs)* Biobrane: 3.1 +/- 0.5 
SSD: 3.7 +/- 0.6 
(Range: Not reported) 
Biobrane: 18.3 +/- 2.6 
SSD: 22.1 +/- 3.5 
(Range: 8 mo-79 yrs) 
Biobrane: 2.8 +/- 0.5 
SSD: 3.4 +/- 0.6 
(Range: Not reported) 
Burn BSA (mean %) * Biobrane: 8.9 +/- 4.9 
SSD: 7.8 +/- 0.9 
Biobrane: 2.0 +/- 0.3 
SSD: 2.4 +/- 0.5 
Biobrane: 11.8 +/- 1.1 
SSD: 11.5 +/- 0.9 
Inclusion Criteria -0-17 yrs old 
-Partial-thickness burn 
-Thermal or scald injury 
-Burned BSA 2-29% 
-Admitted within 24 hrs 
-Clean, non-infected 
wound 
- >2 mo of age 
-Partial-thickness burn 
-Burn <24 hrs old 
-Wounds with “moist, 
sensate surface” and 
appropriate capillary 
refill 
- <17 yrs old 
-Hot fluid, non-grease 
burns 
-Superficial 2
nd
 degree 
(partial-thickness) burns 
-5-25% of total BSA 
-In hospital within 48 hrs 
of burn injury 
Exclusion Criteria - >17 yrs old 
-Causes other than 
thermal or scalding 
-Full-thickness burns 
-Time to admission >24 
hrs 
-Contaminated or 
infected wounds 
- <2 mo old 
-Pregnant 
-Chemical or electrical 
burns 
-Full-thickness burns 
-Wounds >24 hrs old 
-History of sulfa 
sensitivity 
-Gross contamination 
-Treated with any 
topical agent before 
Emerg Dept arrival 
- >17 yrs old 
-Grease burns and non-
scald burns 
-Burns <5% or >25% 
BSA 
-Appear initially to need 
skin grafting 
-Full-thickness burns 
-Burns >48 hrs old 
Withdrawals 0 12 10 
Interventions 1% SSD versus 
Biobrane application 
1% SSD versus 
Biobrane application 
1% SSD versus 
Biobrane application 
(Note: Burns to head / 
neck in SSD group were 
treated with polymyxin / 
bacitracin) 
 
* Differences in age and total burn body surface area were not statistically significant, as reported by each study 
 
Data Analysis 
Data from each study was examined for healing times, amount of pain, length of hospital stay, 
and number of complications.  Two of the trials did not specifically study amount of pain and 
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length of hospital stay.  An overall review of the outcomes from each study can be found in 
Table 2. 
Table 2 
Overall review of outcomes from studies comparing Biobrane to SSD 
Outcome Study 
 Barret 
6
 Gerding 
2
 Lal 
7
 
Healing time Decreased in Biobrane 
group (p < 0.001) 
Decreased in Biobrane 
group (p < 0.01) 
Decreased in Biobrane 
group (p < 0.05) 
Pain scores Decreased in Biobrane 
group (p < 0.001) 
Decreased in Biobrane 
group (p < 0.001) 
--- 
Complications NS NS NS 
Length of hospital stay Decreased in Biobrane 
group (p = 0.017) 
--- Decreased in Biobrane 
group (p < 0.05) 
 
Differences noted were all statistically significant 
“---“ indicates that the study did not report or specifically study the outcome 
“NS” indicates no statistically significant difference between the Biobrane and SSD groups 
 
Healing Time 
Healing time was defined relatively similarly in each of the three studies as the time required to 
attain complete wound closure or re-epithelialization.  One of the studies estimated wound 
healing time as the midpoint between the date when wound closure was documented in the 
follow-up note and the previous visit.
7
  After taking into account the number of subjects and 
combining the mean healing times from each study, an overall mean average healing time was 
attained, as well as a percentage change between the Biobrane and SSD treatments (Table 3).  
Overall, healing times were reduced by approximately 61% in subjects treated with Biobrane. 
Length of Hospital Stay 
The length of hospital stay was reported in two of the three studies.
6,7
  The total number of 
subjects were taken into account and mean lengths of stay were combined to produce an overall 
mean length of hospital stay for each treatment group.  The overall length of hospital stay was 
reduced by approximately 48% in the Biobrane-treated group (Table 3). 
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Amount of Pain 
Pain scores were assessed in two of the three included studies.
2,6
  Each of these two studies 
assessed pain on a 5 level linear scale, with lower numbers correlating to less pain and higher 
numbers more pain.  Because the Barret
6
 study assessed pain on a 0 to 4 scale, and the Gerding
2
 
study on a 1 to 5 scale, a uniform scale ranging from 1 to 5 was adopted during analysis and the 
Barret scores were adjusted to reflect the change.  The mean total pain scores were combined, 
taking into account the number of subjects, and produced an overall mean pain score.  The 
overall pain scores were reduced by 54% in the group treated with Biobrane (Table 3). 
Table 3 
 
Summary from the analysis of outcomes: Biobrane versus SSD 
   Treatments ( mean averages)  
Outcomes # of studies # of subjects Biobrane SSD Change in 
Biobrane group (%) 
Healing Time 3 151 13.2 * 21.5 - 61.4 
Hospital Stay 2 99 2.5 * 5.2 - 48.2 
Pain Scores 2 72 2.1 ** 3.9 - 54.0 
 
* Healing time & Hospital stay are reported in days 
** Pain scores are reported on a linear scale (1=least pain; 5=most pain) 
 
Complications of Treatment: 
Complications of treatment were defined as the apparent development of infection or need for 
skin grafting after the treatment method had begun.  Each of the three studies reported 
complications.  The number of complications were combined, and produced an overall 
complication of treatment percentage (Table 4).  Overall, 5 subjects in the Biobrane group and 4 
subjects in the SSD group had complications of treatment.  In the Biobrane group 7.1% of 
subjects experienced a complication, whereas in the SSD group 4.9% had a complication of 
treatment.  For the purpose of complication analysis, Biobrane was considered the “treatment” 
group and SSD was considered the “control” group.  The relative risk of complication was 
increased in the Biobrane group, and the absolute risk of complication was 2.2% higher in the 
Biobrane treatment group.  Chi-square analysis shows that the increased number of 
complications in the Biobrane group is not statistically significant compared with the 
complications experienced in the SSD group (p=0.33).
8
 
It should be noted that Biobrane, compared to SSD, has the potential for a unique type of 
complication: non-adherence to the wound.  Two subjects in the Lal study experienced non-
adherence of the Biobrane and were analyzed in the Biobrane group as intent-to-treat.
7
  For this 
review, these two subjects were not counted as complications in the Biobrane treatment group 
because infection or the need for skin grafting did not occur.  Had the two non-adherence 
complications been included, the number of Biobrane complications was still not statistically 
significant as compared to SSD complications. 
Table 4 
 
Summary of complications comparing Biobrane to SSD 
   Subjects w/ Outcome (%)   
Outcome # of 
studies 
# of 
subjects 
Biobrane SSD Relative 
Risk 
Absolute Risk 
Reduction (%) 
Complications 
of treatment * 
3 151 7.1 4.9 1.45 - 2.2 
 
* Complications were considered development of infection or need for skin grafting after beginning specific treatment 
 
 
 
DISCUSSION: 
The findings from this review support the use of Biobrane in the treatment of partial-thickness 
burns affecting a body surface area of less than 20%.  Compared to silver sulfadiazine, Biobrane 
appears to have a clinically significant reduction in healing time, length of hospital stay, and 
amount of pain.  Fewer dressing changes are necessary and the need for daily debridement of 
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wound sites is not necessary in patients using Biobrane—this likely has an impact on this lower 
pain scores demonstrated in the Biobrane treatment group. Complications experienced between 
the two groups were not significantly different in terms of number of complications.  Users of 
Biobrane, however, must be aware of the potential for the material to become non-adherent to 
the wound—essentially making a closed wound into an open wound and likely increasing the 
chance for infection. 
Limitations 
This review has some limitations that should be noted.  Attempts to find all available data 
comparing Biobrane to SSD revealed a number of studies and total number of subjects that 
remains small.  The included studies also focused on varying age ranges and fairly large 
differences in the percent BSA burned.  Therefore, this review has limited power to detect the 
differences present in a specific age group or a specific percentage of BSA burned. 
Each of the included trials appeared to be of fair to good quality, however there were a few 
limitations noted.  All three of the trials did not study each of the outcomes addressed in this 
review—in fact only two of the outcomes (healing time and complications) were addressed by all 
three of the included studies.  Because of this, results dealing with pain scores and hospital stay 
have a smaller total sample size and likely have less ability to predict outcomes in the general 
population.  Only one of the three studies (Lal
7
) specifically mentioned how subjects who 
withdrew from the study were analyzed. 
Although this review suggests that Biobrane appears to reduce the healing time, length of 
hospital stay, and pain level of subjects; caution must be taken in applying the results of this 
review to the general population, as the results may be significantly different.  
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It should also be noted that the American Burn Association recommends referral of partial 
thickness burns >10% BSA to a burn specialty center.
1
  Because a number of the subjects studied 
in these trials had burns near or slightly above 10% total BSA, the transferability of results to 
patients with significantly lower percent burned BSA—as may be seen and managed in a 
primary care or local emergency department setting—must be interpreted cautiously.  
Conclusions 
Data from this review implies that Biobrane is more effective than SSD at reducing healing time, 
pain scores, and length of hospital stay in patients with partial-thickness burns affecting a BSA 
less that 20%.  Although complications encountered with Biobrane are similar in number to 
those encountered with SSD, extra care must be taken when using Biobrane to ensure adherence 
of the Biobrane mesh to the wound site.  In order to more accurately apply these results to the 
general population, future research employing a larger sample population size and addressing a 
more specific age range or size of burn wound would be beneficial. 
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